---
name: redteam-convergence-verdict-2026-05-01
description: Three-pass red team converged on 3 CRITICAL blockers: HSA regulatory framing, no verified purchase intent, 30-day value void
type: RISK
date: 2026-05-01
author: agent
session_id: current
project: chronic-prevention
topic: Red team convergence verdict — Metabo market opportunity
phase: redteam
tags: [redteam, critical-findings, market-feasibility, hsa, b2b2c, engagement-loop]
---

## Red Team Convergence Results (3 Independent Passes)

**Prior session** (analyst, redteam-findings.md + journals 0001–0009):
- GAP-1: HRV-as-metabolic-proxy unvalidated
- GAP-2: No evidence nudges change HbA1c trajectories
- GAP-3: Wearable penetration overestimated (15–25% vs 40% assumed)
- GAP-4: B2B2C employer channel unvalidated
- GAP-5: Social proof number (8,200) fabricated
- GAP-6: NHANES calibration gap for Malay/Indian users
- GAP-7: Hawker meal model Chinese-centric
- GAP-8: No willingness-to-pay validation
- RISK: USP is behavioral loop, not ML sophistication

**Market feasibility agent** (2026-05-01):
- CRIT-1: HSA wellness tier framing legally unstable (intended use ≠ output vocabulary)
- CRIT-2: B2B2C no verified purchase intent (Aon survey shows diabetes prevention not a listed employer priority category)
- HIGH-1: Engagement loop not demonstrably differentiated (Hawthorne effect is actual mechanism, not ML)
- HIGH-2: NHANES ethnicity categories not transferable to Singapore demography
- HIGH-3: Market timing "NOW" self-contradictory (HSA guidance both enabler and risk)

**Value-auditor agent** (2026-05-01):
- CRIT: 30-day value void kills B2C conversion (users pay upfront, main score unavailable for 30 days)
- CRIT: No Singapore validation data (disqualifies B2B2C, insurance, government buyers)
- HIGH: <30% utilisation is structural (employer surveillance concerns + no felt personal benefit)
- HIGH: NHANES model credibility gap for diverse workforces
- HIGH: HSA regulatory boundary risk

## Converged CRITICAL Findings (all 3 passes)

1. **HSA regulatory framing** — product may be Class B medical device regardless of output vocabulary; legal opinion mandatory before proceeding
2. **No verified purchase intent** — zero customer discovery; B2B2C theoretically plausible but empirically unvalidated
3. **30-day value void** — B2C conversion funnel has structural hole; preliminary score needed on Day 1

## For Discussion

1. Is the founder willing to spend on regulatory legal opinion before any engineering investment? If HSA says Class B, the entire product architecture changes.
2. Could a B2C waitlist / smoke test validate purchase intent before committing to engineering? This would be faster and cheaper than HR manager interviews.
3. Is a "population-referenced Day 1 score" technically feasible given the NHANES model structure? If yes, this single change makes the B2C funnel viable.
